Abstract
Background Osteoporosis, cardiovascular diseases (CVD), and metabolic syndrome (MS) are associated with a higher mortality rate. Bone tissues, adipocytes, and the brain interact together to control body weight and regulate glucose metabolism through osteocalcin (OC), a hormone secreted by the osteoblasts. The aim of our study was to establish the correlation between serum osteocalcin levels, features of MS and cardiovascular risk assessed through non-HDL-cholesterol levels in a group of postmenopausal women.
Methods Retrospective study conducted over a period of 3 years on a group of 150 postmenopausal women, divided into two lots according to the presence or absence of MS. The diagnosis of MS was made based on NCEP ATP - III criteria. Serum osteocalcin has been correlated with specific components of MS and other atherogenic markers.
Results OC values were lower in patients with MS compared to those without MS. Significant negative correlations were recorded between OC and the fasting values of blood glucose, body mass index (BMI), and triglyceride levels. The most accurate atherogenic risk parameter non-HDL-cholesterol was significantly and negatively correlated with OC. Positive and significant correlations were recorded between the values of HDL-cholesterol and OC (R² = 0.033; P < 0.05). All these results sustain the significant association between dyslipidemia, the alteration of glucose metabolism, and OC in postmenopausal women with MS.
Conclusions The correlation between pro-atherogenic lipid fractions (non-HDL cholesterol) and osteocalcin is of real interest. Low serum values of osteocalcin may represent a metabolic marker of cardiovascular risk.
Keywords
References
Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117–9.
Tan A, Gao Y, Yang X, Zhang H, Qin X, Mo L, et al. Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey. Metabolism. 2011;60(8):1186–92.
Saleem U, Mosley TH Jr, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2010;30(7):1474–8.
Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Annals of Clini Biochem. 2000;37:432–46.
García-Martín A, Cortés-Berdonces M, Luque-Fernández I, Rozas-Moreno P, Quesada-Charneco M, Muñoz-Torres M. Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. Menopause. 2011;18(5):537–41.
Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105(13):5266–70.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69.
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(1):45–9.
Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab.1997;82(9):2915–20.
Pal SN, Rush C, Parr A, Van Campenhout A, Golledge J. Osteocalcin positive mononuclear cells are associated with the severity of aortic calcification. Atherosclerosis. 2010;210(1):88–93.
Gössl M, Mödder UI, Atkinson EJ, Lerman A, Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol. 2008; 52(16):1314–25.
Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21(12):1998–2003.
Alfadda AA, Masood A, Shaik SA, Dekhil H, Goran M. Association between osteocalcin, metabolic syndrome, and cardiovascular risk factors: role of total and undercarboxylated osteocalcin in patients with type 2 diabetes. Int J Endocrinol. 2013; Article ID: 197519, p. 6.
Yeap BB, Chubb SA, Flicker L, et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The health in men study. Osteoporos Int. 2012;23(2):599–606.
Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol. 2012;28(6):472–7.
Oosterwerff MM, van Schoor NM, Lips P, Eekhoff EM. Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. Clin Endocrinol (Oxf). 2013;78(2):242–7.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.
Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Intl. 2014;2014:757461.
Virani SS. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011; 38(2):160–2.
Maser RE, Lenhard MJ, Sneider MB, Pohlig RT. Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes. Endocr Pract. 2015;21(1):14–22.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.